Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status. (Q45907272)
Jump to navigation
Jump to search
scientific article published on 4 November 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status. |
scientific article published on 4 November 2015 |
Statements
1 reference
Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status. (English)
1 reference
Naiyer Rizvi
1 reference
Jamie Chaft
1 reference
Ani Balmanoukian
1 reference
Sarah B Goldberg
1 reference
Rachel E Sanborn
1 reference
Keith E Steele
1 reference
Marlon C Rebelatto
1 reference
Yu Gu
1 reference
Joyson J Karakunnel
1 reference
Scott Antonia
1 reference
4 November 2015
1 reference
3
1 reference
Suppl 2
1 reference
P193-P193
1 reference
Identifiers
1 reference